Study guide
13.3 Pharmacovigilance, Recall & Medicine Disposal
DHA Pharmacist Licensing Assessment PHO5481
Track your progress as you read
Finished sections get a check mark.
1 Exam Overview & Licensing Pathway
1.1 Current Exam Facts & Format 1.2 Eligibility, PQR & the Sheryan Application Process 1.3 Study Strategy & Test-Day Plan
2 Cardiovascular Pharmacology
2.1 Antihypertensives & RAAS Agents 2.2 Heart Failure & Antiarrhythmic Drugs 2.3 Lipid-Lowering & Antianginal Agents
3 Endocrine & Metabolic Pharmacology
3.1 Insulin & Oral Antidiabetic Agents 3.2 Thyroid, Bone & Calcium Agents 3.3 Corticosteroids & Other Hormonal Agents
4 Anti-Infective Pharmacology
4.1 Beta-Lactam Antibiotics 4.2 Non-Beta-Lactam Antibacterials 4.3 Antifungals, Antivirals & Antituberculars
5 CNS, Psychiatric & Pain Pharmacology
5.1 Psychiatric Pharmacology 5.2 Antiepileptics & Neurologic Agents 5.3 Analgesics: NSAIDs, Opioids & Migraine
6 Respiratory, GI & Hematology Pharmacology
6.1 Respiratory Pharmacology 6.2 Gastrointestinal Pharmacology 6.3 Anticoagulants, Antiplatelets & Hematology Agents
7 Pharmaceutical Care: Cardiometabolic Disease
7.1 Diabetes Management & Counseling 7.2 Hypertension & Dyslipidemia Management 7.3 Heart Failure & Anticoagulation Management
8 Pharmaceutical Care: Respiratory, Rheumatology & Infection
8.1 Asthma & COPD Management 8.2 Gout, Pain & Rheumatologic Care 8.3 Infection Management & Antimicrobial Stewardship
9 Counseling, Monitoring & Special Populations
9.1 Patient Counseling, Adherence & Health Literacy 9.2 Therapeutic Monitoring & Laboratory Interpretation 9.3 Pregnancy, Pediatrics, Geriatrics & Organ Impairment 9.4 Pharmacoeconomics & Formulary Decision Making
10 Pharmaceutical Calculations I
10.1 Concentration, Ratio & Percentage Strength 10.2 Weight-Based & BSA Dosing 10.3 Dilution, Concentration & Alligation
11 Pharmaceutical Calculations II
11.1 Infusion Rates & IV Flow Calculations 11.2 Dispensing Quantities & Days' Supply 11.3 Compounding Calculations, Isotonicity & Milliequivalents
12 UAE Pharmacy Law & Regulation
12.1 UAE Regulatory Framework & Licensing Authorities 12.2 Medicine Registration, Pricing & Supply Chain 12.3 Prescription Requirements & Validity
13 Controlled Drugs, Ethics & Pharmacovigilance
13.1 Controlled & Semi-Controlled Medicines in the UAE 13.2 Ethics, Confidentiality & Generic Substitution 13.3 Pharmacovigilance, Recall & Medicine Disposal
14 Pharmacokinetics I: ADME
14.1 Absorption & Bioavailability 14.2 Distribution & Protein Binding 14.3 Metabolism & Elimination
15 Pharmacokinetics II: Kinetics, Dosing & TDM
15.1 Half-Life, Clearance & Kinetic Order 15.2 Loading & Maintenance Dosing 15.3 Therapeutic Drug Monitoring
16 OTC Medicines & Self-Care
16.1 Cough, Cold & Allergic Rhinitis 16.2 GI Self-Care: Heartburn, Constipation & Diarrhoea 16.3 Pain & Fever Self-Care 16.4 Referral Red Flags, Emergency Contraception & Skin
17 Medication Safety
17.1 High-Alert Medications & Error-Prone Abbreviations 17.2 Medication Reconciliation & Duplicate Therapy 17.3 Adverse Drug Reactions & Hypersensitivity Recognition
18 Sterile & Nonsterile Compounding
18.1 Aseptic Technique & Compounding Environments 18.2 Parenteral, TPN & Cytotoxic Preparation 18.3 Nonsterile Compounding
19 Pharmaceutics, Biopharmaceutics & Toxicology
19.1 Dosage Form Design & the Biopharmaceutics Classification System 19.2 Dissolution & Excipients 19.3 Toxicology: Poisoning Recognition & Antidotes
20 Infection Control, Natural Products, Medicinal Chemistry & Pharmacogenomics
20.1 Infection Control & Immunization 20.2 Pharmacognosy & Dietary Supplements 20.3 Medicinal Chemistry Essentials 20.4 Clinical Pharmacogenomics
13.3 Pharmacovigilance, Recall & Medicine Disposal
Key Takeaways Explain This Topic AI
Pharmacovigilance is post-marketing safety surveillance — clinical trials cannot detect rare or long-latency harms
Pharmacists should report suspected adverse drug reactions, medication errors and quality defects through the UAE national system via EDE and DHA channels
A minimum viable report needs an identifiable patient, an identifiable reporter, a suspect drug and a reaction
On a recall, the pharmacy quarantines affected stock, identifies and contacts supplied patients where directed, and documents the return
Expired and unused medicines never go to household waste or sewage; controlled-drug disposal requires witnessed destruction and cytotoxic waste is segregated
Last updated: August 2026
Why Pharmacovigilance Exists
Pharmacovigilance (PV) is the science and activity of detecting, assessing, understanding and preventing adverse effects and other medicine-related problems after marketing authorisation . Pre-marketing clinical trials enrol limited, selected populations for limited durations, so they cannot detect rare reactions , long-latency harms , or effects in groups excluded from trials — pregnant women, the very old, patients with multiple comorbidities. Post-marketing surveillance by the whole health system is therefore the only realistic way to catch these signals, which is why regulators can restrict, re-label or withdraw products years after launch. The UAE participates in the international reporting network coordinated through the World Health Organization's programme, and operates a national system under the federal medicines regulator — the Emirates Drug Establishment (EDE) — with Dubai Health (DHA) providing reporting channels for facilities and professionals in Dubai.
Who reports, and what
Any healthcare professional — explicitly including pharmacists — should report, and patients may report too. The duty attaches to suspicion : you do not need to prove causality before reporting. Report:
Serious suspected adverse drug reactions (ADRs) — fatal, life-threatening, causing hospitalisation, disability or congenital harm.
Unexpected reactions — not consistent with the approved product information, even if mild.
Reactions to new medicines under enhanced surveillance (the black-triangle concept used internationally: an inverted triangle on product information flags a new drug for intensive reporting of all suspected reactions).
Medication errors that caused or could have caused harm, and lack of efficacy where it matters clinically (for example, contraceptive or anti-infective failure).
Product quality defects — contamination, mislabelling, crumbling tablets, particulate matter in injections.
Minimum reportable information
A report is considered valid when it contains four elements — an easy exam mnemonic:
An identifiable patient (initials, age, sex suffice — not necessarily a name).
An identifiable reporter (so the authority can follow up).
A suspect drug (brand or generic name, strength, batch where known).
A suspected reaction (description, onset, outcome).
Reports are assessed for causality — the likelihood the drug caused the event, from certain through probable and possible to unlikely — using timing, dechallenge, rechallenge and alternative explanations. Pharmacists should know the concept and the factors, not a scoring formula.
Medicine Recalls
A recall is the removal or correction of a marketed product that violates standards or presents a risk. Recalls are graded by severity — the international convention used in regional guidance:
Class Risk level Typical trigger Example action
Class I Serious risk of death or serious harm Contamination, wrong active ingredient, sterility failure Urgent removal to patient level; direct patient contact
Class II Temporary or reversible harm, or low probability of serious harm Sub-potency, labelling error with clinical impact Retrieval to pharmacy/wholesale level
Class III Unlikely to cause harm; technical breach Minor labelling or packaging non-compliance Stock-level correction
Pharmacy obligations on recall notification: identify and quarantine affected stock (physically segregate and label it so it cannot be dispensed), reconcile against the batch numbers in the notice, identify and contact patients who received the affected batch where the notice directs patient-level recall, document every step — quantities found, patients contacted, stock returned — and return or destroy the stock only through the authorised route specified by the authority or the marketing-authorisation holder. A defective product identified locally (before any recall) should likewise be quarantined, reported as a quality defect, and never dispensed or silently returned to the shelf.
Safe Disposal of Expired and Unused Medicines
Expired, damaged or unwanted medicines are pharmaceutical waste , not ordinary refuse. Core rules:
Never dispose of medicines in household waste, and never flush them into sinks or toilets — sewage systems are not designed to remove pharmaceuticals, and landfill leaching contaminates the environment.
Pharmacies accept or arrange the return of unwanted medicines from patients and channel expired stock to an authorised pharmaceutical-waste handler for high-temperature incineration or an equivalent approved method, with documented transfer.
Controlled drugs require the stricter route already covered in Section 13.1: prior authorisation and witnessed, documented destruction , with the register annotated.
Cytotoxic and hazardous medicines (chemotherapy agents, certain antivirals and hormones) are segregated into designated hazardous-waste containers and handled with protective precautions by trained handlers — they are never mixed with general pharmaceutical waste.
Sharps — needles, lancets, broken ampoules — go immediately into a puncture-resistant sharps container , which is sealed and replaced before overfilling and disposed of through the clinical-waste stream. Never recap needles by hand, never place sharps in general waste bags, and never overfill past the fill line.
Selling expired stock, repackaging near-expiry products, or discarding medicines in ordinary rubbish are all exam-level examples of professional misconduct with regulatory and environmental consequences.